Doxorubicin-resistant cell lines predominantly featured mutations in TP53, whereas Doxorubicin-sensitive cell lines exhibited a broader array of mutations in genes such as RYR1, IDH1, and SDHA, which were frequently observed in Doxorubicin-sensitive cell lines across both Cancer Cell Line Encyclopedia (CCLE) and SNU cohorts (Fig. 2A). This evidence concerns the gene RYR1 and cancer.